NLNK vs. EBS, RGLS, BOLT, FBIO, RIGL, MACK, VSTM, VNDA, XOMA, and ELYM
Should you be buying NewLink Genetics stock or one of its competitors? The main competitors of NewLink Genetics include Emergent BioSolutions (EBS), Regulus Therapeutics (RGLS), Bolt Biotherapeutics (BOLT), Fortress Biotech (FBIO), Rigel Pharmaceuticals (RIGL), Merrimack Pharmaceuticals (MACK), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), and Eliem Therapeutics (ELYM). These companies are all part of the "medical" sector.
NewLink Genetics (NASDAQ:NLNK) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.
Emergent BioSolutions has a consensus price target of $5.00, suggesting a potential upside of 160.42%. Given Emergent BioSolutions' higher probable upside, analysts plainly believe Emergent BioSolutions is more favorable than NewLink Genetics.
In the previous week, Emergent BioSolutions had 4 more articles in the media than NewLink Genetics. MarketBeat recorded 4 mentions for Emergent BioSolutions and 0 mentions for NewLink Genetics. Emergent BioSolutions' average media sentiment score of 0.20 beat NewLink Genetics' score of 0.00 indicating that Emergent BioSolutions is being referred to more favorably in the news media.
Emergent BioSolutions received 27 more outperform votes than NewLink Genetics when rated by MarketBeat users. However, 71.56% of users gave NewLink Genetics an outperform vote while only 66.45% of users gave Emergent BioSolutions an outperform vote.
Emergent BioSolutions has a net margin of -72.11% compared to NewLink Genetics' net margin of -4,592.84%. Emergent BioSolutions' return on equity of -37.35% beat NewLink Genetics' return on equity.
NewLink Genetics has higher earnings, but lower revenue than Emergent BioSolutions. NewLink Genetics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
NewLink Genetics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
32.3% of NewLink Genetics shares are owned by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are owned by institutional investors. 12.7% of NewLink Genetics shares are owned by insiders. Comparatively, 1.2% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Emergent BioSolutions beats NewLink Genetics on 12 of the 17 factors compared between the two stocks.
Get NewLink Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLNK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NewLink Genetics Competitors List
Related Companies and Tools
